NCT04460183View on ClinicalTrials.gov

A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

April 24, 2021

Study Completion Date

May 21, 2021

Conditions

COVID-19

Interventions

DRUG

RESP301, a Nitric Oxide generating solution

Product application requires inhalation using a standard handheld nebulizer.

OTHER

Standard of Care

Participants will receive institutional SOC for the treatment of COVID-19.

Trial Locations (2)

W2 1NY

Imperial College Healthcare NHS Trust, St. Mary's Hospital, London

PR2 9HT

Royal Preston Hospital, Preston

All Listed Sponsors

lead

Thirty Respiratory Limited

INDUSTRY

NCT04460183 - A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19 | Biotech Hunter | Biotech Hunter